

ASX ANNOUNCEMENT

BENITEC BIOPHARMA LIMITED (NASDAQ: BNTC; NASDAQ: BNTCW; ASX: BLT)

24 August 2015

CEO OF BENITEC BIOPHARMA DISCUSSES THE COMPANY'S NASDAQ LISTING

Sydney Australia: Benitec Biopharma Limited (NASDAQ: BNTC; NASDAQ: BNTCW; ASX: BLT) is pleased to invite investors to listen to an audio interview of Managing Director and CEO, Dr Peter French discussing the successful capital raise and NASDAQ listing.

To listen to the audio, please copy the following link into your browser:

http://www.brrmedia.com/event/140119

Ends -

This announcement has been prepared for publication in Australia and may not be released in the United States. This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or any other jurisdiction.

For further information regarding Benitec and its activities, please contact the persons below, or visit the Benitec website at www.benitec.com.

| Company | Investor relations |
|-------------------------------|------------------------------------|
| Carl Stubbings | Kyahn Williamson |
| Chief Business Officer | Buchan Consulting |
| Tel: +61 (2) 9555 6986 | Tel: +61 (3) 9866 4722 |
| Email: cstubbings@benitec.com | Email: kwilliamson@buchanwe.com.au |

About Benitec Biopharma Limited:

Benitec Biopharma Limited is a biotechnology company, which has developed a patented gene silencing technology delivered by gene therapy, called DNA directed RNA interference (ddRNAi) that has the potential to produce 'one-shot' cures for a range of diseases. The company is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including hepatitis C and B, drug resistant lung cancer and wet age-related macular degeneration. Benitec has also licensed ddRNAi to other biopharmaceutical companies for applications including HIV/AIDS, Huntington's disease, chronic neuropathic pain and retinitis pigmentosa. For more information visit www.benitec.com.